What Is the T2 Hormone and What Does It Do?

3,5-Diiodo-L-thyronine, usually called T2, is a naturally occurring metabolite of the better-known thyroid hormones T4 (thyroxine) and T3 (triiodothyronine). For decades it was dismissed as an inert breakdown product, but over thirty years of research have revealed that T2 has real biological activity, particularly in how the body handles fat and energy expenditure.¹ It sits in an unusual space: too active to ignore, too poorly understood to use clinically, and already showing up in over-the-counter supplements with questionable labeling.

How Your Body Makes T2

T2 is not produced by the thyroid gland directly. Instead, it is generated from T4 and T3 through a family of enzymes called deiodinases, which strip iodine atoms off the larger thyroid hormones one at a time. Two pathways converge on 3,5-T2. One route goes through T3: the enzyme D3, which has inner-ring deiodinase activity, removes an iodine from T3 to produce 3,3′-T2. The other route goes through reverse T3 (rT3), an inactive form of T3: the enzymes D1 and D2, which have outer-ring activity, degrade rT3 into 3,3′-T2 as well.² The specific isomer that has drawn the most research attention, though, is 3,5-T2, which has both of its iodine atoms on the outer ring. This distinction matters because the different T2 isomers do not behave the same way in the body.

Because T2 is a downstream product of T4 and T3, its levels in the blood depend on how actively those conversion enzymes are working. The deiodinase enzyme DIO2 is particularly important in local tissue conversion. Research on thyroid cancer patients has found that people with lower DIO2 expression in thyroid tissue tend to have higher TSH levels even during hormone-suppression therapy, which hints at how tightly the whole conversion chain is regulated and how disruptions upstream can ripple downstream.³

What T2 Does at the Mitochondrial Level

The most consistent finding about T2, across species and tissue types, is that it targets mitochondria. Mitochondria are the structures inside cells that burn fuel and produce energy, and T2 appears to rev them up. In skeletal muscle, T2 stimulates respiratory chain activity, boosts mitochondrial heat production (thermogenesis), and speeds up the way mitochondria process fats.⁴ These effects happen rapidly, which is unusual for thyroid-related hormones. Classic thyroid hormone action involves binding to nuclear receptors and changing gene expression over hours or days. T2 seems to act more quickly, working directly on the mitochondrial machinery itself.

One piece of that machinery is cytochrome c oxidase, a key enzyme in the mitochondrial electron transport chain. Research has shown that T2, along with T3 and T4, can bind to this enzyme and inhibit the generation of superoxide, a harmful reactive oxygen species, when the enzyme is exposed to excess hydrogen peroxide. The inhibition occurs at very low concentrations, and T2 appears to bind tightly to a specific subunit of the enzyme called subunit Va.⁵ In plain terms, T2 may help protect cells from oxidative damage at the mitochondrial level, in addition to boosting energy output.

Fat Burning and the “Browning” of White Fat

The metabolic effect that has generated the most excitement around T2 is its ability to reduce fat accumulation. In rats fed a high-fat diet, T2 treatment reduced the buildup of fat in the liver. At the mitochondrial level, T2 enhanced the rate at which fatty acids were burned and improved the activity of a key enzyme involved in shuttling fats into mitochondria. It also promoted a less efficient use of those fatty acid fuels through mitochondrial uncoupling, meaning the cells burned more fat but converted less of it into usable energy, instead releasing it as heat. This uncoupling also reduced oxidative stress in the mitochondria.⁶

T2 also appears to influence what kind of fat the body maintains. White fat stores energy; brown fat burns it to generate heat. In overweight male rats kept at thermoneutral temperatures (where the body has no thermal reason to activate brown fat), T2 treatment was able to induce a “browning” process in white fat tissue, essentially pushing the fat cells toward a more metabolically active state. The researchers found that specific microRNAs and a signaling enzyme called MAP kinase 6 were involved in triggering this shift.⁷ Browning of white fat is a hot topic in obesity research more broadly, and T2’s ability to stimulate it in animal models is one reason the molecule attracts interest from the pharmaceutical world.

T2 Is Not Just a Weaker Version of T3

An easy assumption would be that T2 simply does what T3 does, only less potently. The reality is more interesting. When researchers treated tilapia fish with T2 and T3 and compared the gene expression changes in brain and liver tissue, they found remarkably little overlap. In the liver, 929 genes were exclusively regulated by T2, compared to 349 genes exclusively regulated by T3. In the brain, T2 and T3 also regulated largely distinct sets of genes. The pathways affected were different too: T2 influenced gene networks tied to cell signaling and transcriptional regulation, while T3 was more involved in immune system and lipid metabolism pathways.⁸

These findings come from fish, so translating them directly to humans requires caution. But the central takeaway holds: T2 is not simply a diluted form of T3. It appears to have its own distinct regulatory role, activating and suppressing genes that T3 does not touch. This is an important conceptual shift, because it means T2 could have therapeutic applications that do not simply duplicate existing thyroid hormone treatments.

What Elevated T2 Levels in the Blood Might Mean

Measuring T2 in human blood is itself a challenge. The concentrations are extremely low, and until recently the immunoassays used to detect it were not particularly reliable. Newer liquid chromatography-mass spectrometry methods can now detect free T2 at limits as low as 0.002 to 0.008 picomoles per liter, a significant improvement in sensitivity compared to older approaches.⁹ Standard clinical thyroid panels do not include T2, so most people with thyroid conditions have never had it measured.

When researchers have measured circulating T2, the results suggest it may act as a marker for metabolic stress rather than well-being. Elevated 3,5-T2 serum concentrations have been found in people with impaired kidney function, those on chronic dialysis, patients with sepsis, ICU patients who did not survive, and patients who developed atrial fibrillation after surgery.¹⁰ The pattern is striking: T2 goes up in situations where the body is under significant physiological strain. Whether the elevated T2 is contributing to the problem, compensating for it, or simply reflecting altered thyroid hormone metabolism in sick patients remains an open question. The “Janus-faced” description used by some researchers captures this tension well: the same molecule that burns fat and boosts mitochondria in animal models seems to spike under some of the most dangerous clinical conditions in humans.

T2 in Dietary Supplements

Despite the lack of human clinical trials, T2 has already made its way into the supplement market. Products marketed as fat burners and metabolic accelerators contain T2 in doses ranging from 50 to 300 micrograms per pill, and they are sold over the counter without a prescription. The marketing language often includes inaccurate claims, such as stating that T2 “stimulates the thyroid gland,” which is not how the molecule works. Many products do not disclose appropriate warnings about potential side effects or provide clear directions about safe daily doses. To make matters murkier, T2 is frequently combined with other compounds that have overlapping metabolic effects, making it difficult to attribute any outcome specifically to T2.¹¹

The concern here is not just ineffectiveness. T2 is biologically active, and its effects on mitochondrial function and energy metabolism are real at the right doses in animal studies. Taking it without medical supervision means you are essentially self-administering a thyroid hormone metabolite with no reliable dosing guidelines, no standardized product formulation, and no clinical evidence that the doses in supplements produce the effects observed in rat studies. The physiological consequences of long-term T2 supplementation in humans are simply unknown. If you are considering a T2-containing supplement for weight loss, it is worth understanding that the research supporting T2’s metabolic effects comes almost entirely from rodent models, not human trials.

Pharmaceutical Development Inspired by T2

Recognizing T2’s metabolic potential but also its limitations as a drug candidate, pharmaceutical researchers have developed synthetic compounds that mimic T2’s mitochondrial effects. The most studied of these is TRC150094, a diiodothyronine mimetic designed to modulate mitochondrial function without the full hormonal baggage of thyroid hormones. The results from human trials have been mixed, illustrating the gap between animal-model promise and clinical reality.

In a Phase 2 trial involving patients with cardiometabolic risk, TRC150094 at doses of 25 to 50 milligrams daily produced modest but statistically significant reductions in fasting plasma glucose and mean arterial blood pressure after 24 weeks. The drug was weight-neutral, lowered some atherogenic lipid fractions, and was generally well tolerated with only mild to moderate adverse events.¹² However, a separate double-blind controlled trial that specifically measured insulin sensitivity in cardiometabolic patients found that 50 milligrams of TRC150094 daily did not improve hepatic or peripheral insulin sensitivity, did not change fasting free fatty acids, and did not reduce liver fat content.¹³

The researchers in the second trial put it plainly: the potent metabolic effects seen in experimental animal models did not translate to meaningful improvement in metabolic homeostasis in human subjects at the tested dose. This disconnect between animal results and human trials is a recurring theme in T2-related research. The molecule clearly does something powerful in rodent and fish models. Whether that translates to safe, effective human therapy is a question that has not been convincingly answered.

The Glucose Connection

Beyond fat metabolism, thyroid hormones in general play a role in how the body handles glucose. Research on peripheral tissues like skeletal muscle and fat cells has demonstrated that thyroid hormone treatment can improve glucose intolerance in diabetic models and increase the levels of GLUT4, a protein that helps shuttle glucose from the bloodstream into cells in response to insulin.¹⁴ T2 specifically may contribute to this effect through its mitochondrial actions, though most of the glucose-related evidence is still in the early stage. The idea of using a thyroid hormone metabolite to improve insulin sensitivity without the cardiac side effects of T3 or T4 is appealing in principle, but the TRC150094 results described above suggest the road from concept to clinic is longer than initially hoped.

Why T2 Has Been So Hard to Study

Several factors have conspired to keep T2 in scientific limbo. First, there is the measurement problem. Standard clinical thyroid panels check TSH, free T4, and sometimes free T3. They do not measure T2, and for most of the molecule’s research history, the available assays were not sensitive or specific enough to reliably quantify it in human blood. The development of high-resolution liquid chromatography-mass spectrometry methods with detection limits in the low femtomolar range has helped, but these techniques are not yet routine in clinical laboratories.⁹

Second, T2 exists in multiple isomeric forms, and the literature is not always clear about which isomer is being studied. The metabolically active form generating the most interest is 3,5-T2, with both iodines on the outer ring. But 3,3′-T2, produced by inner-ring deiodination, behaves differently. Papers that refer simply to “T2” without specifying the isomer can be hard to compare, and some early studies may have used mixtures without realizing it.

Third, the animal models that show the most dramatic effects typically use doses of T2 that are far above normal physiological concentrations. Rats given pharmacological doses of T2 show striking reductions in liver fat, increased energy expenditure, and browning of white adipose tissue. But circulating T2 levels in healthy humans are vanishingly low. Whether boosting those levels to supraphysiological concentrations would be safe over the long term is unknown, especially given that elevated T2 in clinical settings has been associated with critical illness.¹⁰

T2 and Skeletal Muscle

Skeletal muscle is one of the body’s largest consumers of energy, so any molecule that changes mitochondrial efficiency in muscle has outsized metabolic consequences. T2 affects multiple aspects of muscle mitochondrial function at once. It stimulates the respiratory chain (the series of protein complexes that generate the cell’s energy currency), promotes thermogenesis within muscle cells, and enhances the handling and burning of lipid fuels. These effects happen quickly, consistent with T2’s apparent ability to act directly on mitochondrial components rather than working through the slower route of nuclear gene expression.⁴

For anyone interested in exercise physiology, the implications are intriguing but speculative. If T2 genuinely enhances muscle mitochondrial efficiency and fat oxidation, it could theoretically improve endurance performance or recovery. But no human exercise studies have tested this, and the gap between “T2 stimulates rat muscle mitochondria in a lab setting” and “T2 supplements will improve your workout” is enormous. The supplement industry has not waited for that gap to be closed, but anyone evaluating these products should recognize that they are extrapolating from rodent data.

How T2 Fits Into the Broader Thyroid Hormone Picture

The traditional view of thyroid hormone metabolism is relatively straightforward: the thyroid gland secretes mostly T4, tissues convert T4 to the more active T3, and the body degrades both into inactive metabolites. T2 complicates this picture. It is produced through the same degradation pathways that were thought to be simply clearing spent hormones from the system, but it turns out to have its own biological effects that do not neatly mirror those of T3.⁸ This means the cascade of thyroid hormone breakdown is not just a disposal system; it is generating secondary signaling molecules along the way.

Researchers studying thyroid hormone action in liver tissue have described 3,5-T2 as having both “canonical T3-mimetic endocrine” effects and “intracrine hepatic” effects, meaning it can mimic some of T3’s traditional hormone actions while also working inside liver cells through mechanisms T3 does not use.¹⁰ This dual nature is part of what makes T2 difficult to categorize and even more difficult to develop into a therapeutic. It does not fit cleanly into the “active hormone” or “inactive metabolite” bin. It is something in between, with context-dependent effects that change based on the tissue, the dose, and probably the metabolic state of the organism receiving it.